184 related articles for article (PubMed ID: 36329350)
1. Upregulation of cytidine deaminase in NAT1 knockout breast cancer cells.
Hong KU; Tagnedji AH; Doll MA; Walls KM; Hein DW
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5047-5060. PubMed ID: 36329350
[TBL] [Abstract][Full Text] [Related]
2. Deletion of arylamine N-acetyltransferase 1 in MDA-MB-231 human breast cancer cells reduces primary and secondary tumor growth in vivo with no significant effects on metastasis.
Doll MA; Ray AR; Salazar-González RA; Shah PP; Vega AA; Sears SM; Krueger AM; Hong KU; Beverly LJ; Hein DW
Mol Carcinog; 2022 May; 61(5):481-493. PubMed ID: 35133049
[TBL] [Abstract][Full Text] [Related]
3. Mycoplasma infection of cancer cells enhances anti-tumor effect of oxidized methylcytidines.
Pang GZ; Zhao YH; Wang YX; Rong SQ; Gao H; Zhou D
Biochem Biophys Res Commun; 2023 Sep; 672():193-200. PubMed ID: 37356286
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9 knockout of human arylamine N-acetyltransferase 1 in MDA-MB-231 breast cancer cells suggests a role in cellular metabolism.
Carlisle SM; Trainor PJ; Hong KU; Doll MA; Hein DW
Sci Rep; 2020 Jun; 10(1):9804. PubMed ID: 32555504
[TBL] [Abstract][Full Text] [Related]
5. Knockout of human arylamine N-acetyltransferase 1 (NAT1) in MDA-MB-231 breast cancer cells leads to increased reserve capacity, maximum mitochondrial capacity, and glycolytic reserve capacity.
Carlisle SM; Trainor PJ; Doll MA; Stepp MW; Klinge CM; Hein DW
Mol Carcinog; 2018 Nov; 57(11):1458-1466. PubMed ID: 29964355
[TBL] [Abstract][Full Text] [Related]
6. Genetic and small molecule inhibition of arylamine N-acetyltransferase 1 reduces anchorage-independent growth in human breast cancer cell line MDA-MB-231.
Stepp MW; Doll MA; Carlisle SM; States JC; Hein DW
Mol Carcinog; 2018 Apr; 57(4):549-558. PubMed ID: 29315819
[TBL] [Abstract][Full Text] [Related]
7. Contribution of Cytidine Deaminase to Thymidylate Biosynthesis in Trypanosoma brucei: Intracellular Localization and Properties of the Enzyme.
Moro-Bulnes A; Castillo-Acosta VM; Valente M; Carrero-Lérida J; Pérez-Moreno G; Ruiz-Pérez LM; González-Pacanowska D
mSphere; 2019 Aug; 4(4):. PubMed ID: 31391279
[TBL] [Abstract][Full Text] [Related]
8. CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer.
Zauri M; Berridge G; Thézénas ML; Pugh KM; Goldin R; Kessler BM; Kriaucionis S
Nature; 2015 Aug; 524(7563):114-8. PubMed ID: 26200337
[TBL] [Abstract][Full Text] [Related]
9. Stable Isotope Tracing Reveals an Altered Fate of Glucose in
Wise JTF; Yin X; Ma X; Zhang X; Hein DW
Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107601
[TBL] [Abstract][Full Text] [Related]
10. Proteomic analysis of arylamine
Hong KU; Gardner JQ; Doll MA; Stepp MW; Wilkey DW; Benz FW; Cai J; Merchant ML; Hein DW
Toxicol Rep; 2022; 9():1566-1573. PubMed ID: 36158865
[TBL] [Abstract][Full Text] [Related]
11. Arylamine N-acetyltransferase 1 deficiency inhibits drug-induced cell death in breast cancer cells: switch from cytochrome C-dependent apoptosis to necroptosis.
McAleese CE; Butcher NJ; Minchin RF
Breast Cancer Res Treat; 2022 Oct; 195(3):223-236. PubMed ID: 35918499
[TBL] [Abstract][Full Text] [Related]
12. Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levels.
Funamizu N; Lacy CR; Fujita K; Furukawa K; Misawa T; Yanaga K; Manome Y
PLoS One; 2012; 7(5):e37424. PubMed ID: 22616006
[TBL] [Abstract][Full Text] [Related]
13. Human Arylamine
Carlisle SM; Trainor PJ; Doll MA; Hein DW
Front Pharmacol; 2021; 12():803254. PubMed ID: 35046826
[TBL] [Abstract][Full Text] [Related]
14. Trimodal distribution of arylamine N-acetyltransferase 1 mRNA in breast cancer tumors: association with overall survival and drug resistance.
Minchin RF; Butcher NJ
BMC Genomics; 2018 Jul; 19(1):513. PubMed ID: 29969986
[TBL] [Abstract][Full Text] [Related]
15. Cytidine deaminase activity increases in the blood of breast cancer patients.
Buhagiar-Labarchède G; Onclercq-Delic R; Vacher S; Berger F; Bièche I; Stoppa-Lyonnet D; Amor-Guéret M
Sci Rep; 2022 Aug; 12(1):14062. PubMed ID: 35982128
[TBL] [Abstract][Full Text] [Related]
16. Effects of human arylamine N-acetyltransferase I knockdown in triple-negative breast cancer cell lines.
Tiang JM; Butcher NJ; Minchin RF
Cancer Med; 2015 Apr; 4(4):565-74. PubMed ID: 25627111
[TBL] [Abstract][Full Text] [Related]
17. Kinetic studies on 2',2'-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase.
Bouffard DY; Laliberté J; Momparler RL
Biochem Pharmacol; 1993 May; 45(9):1857-61. PubMed ID: 8494545
[TBL] [Abstract][Full Text] [Related]
18. Dataset for proteomic analysis of arylamine
Hong KU; Gardner JQ; Doll MA; Stepp MW; Wilkey DW; Benz FW; Cai J; Merchant ML; Hein DW
Data Brief; 2022 Dec; 45():108634. PubMed ID: 36426076
[TBL] [Abstract][Full Text] [Related]
19. Arylamine
Salazar-González RA; Doll MA; Hein DW
Front Pharmacol; 2022; 13():797469. PubMed ID: 35153780
[TBL] [Abstract][Full Text] [Related]
20. Arylamine
Li P; Butcher NJ; Minchin RF
Mol Pharmacol; 2019 Nov; 96(5):573-579. PubMed ID: 31444237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
